logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Sarepta Pharmaceuticals Jumps on Competitor’s Failure

  +Follow August 16, 2013 9:54AM
Share:
Tickers Mentioned:

Sarepta Therapeutics Inc. (SRPT) experienced a bit of schadenfreude on Aug. 16 as a direct competitor stumbled badly at the finish line.

Competitor GlaxoSmithKline plc (GSK) had been neck-and-neck with Serepta in the race to develop a breakthrough muscle disorder drug to treat Duchenne Muscular Dystrophy. Both drugs were far ahead of the pack in the development process.

That is, until Baird analyst Brian Skorney reported that Glaxo’s drug, drisapersen, has encountered major stumbling blocks on several fronts that could significantly hamper development. Skorney cited clinical, regulatory, and commercials issues with the drug. Most importantly, the drug did not seem to effectively treat symptoms of the disease at the targeted dose.

Serepta’s drug, eteplirsen, so far has seemed to be effective at treating symptoms of Duchenne. Clinical trials have taken place in the UK. On Aug. 7 the company released promising clinical trial information, which will form the basis of their application for US FDA approval in early 2014.

Duchenne is a severely debilitating form of muscular dystrophy. The recessive muscular degenerative disorder affects approximately 1 in 3,600 boys, and life expectancy for sufferers is usually around 25. A drug from either company would be the first on the American market designed to treat the disorder.

The London-based GlaxoSmithKline , which is the fourth largest pharmaceutical company in the world, shrugged off the setback. Their stock is up .33 percent to hit $51.70 a share.

Serepta is up 6.77 percent to hit $34.21 a share.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for GSK
US Consumer News
23 Oct 14 04:35:23
GlaxoSmithKline plc's underperform rating reiterated at Credit Suisse. GBX 1,400 PT. http://t.co/Zv4ESLhSrp $GSK #GSK
Analyst Ratings
23 Oct 14 04:35:09
GlaxoSmithKline plc's underperform rating reiterated at Credit Suisse. GBX 1,400 PT. http://t.co/dGStthgYFw $GSK #GSK
Bidness Etc
23 Oct 14 04:31:24
GSK will consider selling its HIV business to capitalize - http://t.co/iAHVsXRtcB $GSK
Perfor Mance
23 Oct 14 04:07:06
Option Millionaires: nlightn: $GSK,...Drugmakers seek indemnity for new Ebola vaccines http://t.co/v7tXo6YbUo
Bidness Etc
23 Oct 14 04:04:37
J&J and GSK are willing to partner to develop a more effective Ebola treatment - http://t.co/vYFRfCV2L8 $GSK $JNJ
Joe
23 Oct 14 03:41:46
RT @BioStocks: Drugmakers may need indemnity for fast-tracked #Ebola vaccines $JNJ $NLNK $GSK http://t.co/sAe9MjFnqA
Shysterjd
23 Oct 14 03:40:08
RT @BioStocks: Drugmakers may need indemnity for fast-tracked #Ebola vaccines $JNJ $NLNK $GSK http://t.co/sAe9MjFnqA
Ernest
23 Oct 14 03:35:32
RT @fwpharma: "2014 has been a difficult year, a challenging year," says @GSK CEO Witty http://t.co/wtVghhx0go $GSK #pharma
Jacob Plieth
23 Oct 14 03:32:42
Leerink on $GSK's respiratory biz. $THRX http://t.co/bkZAXTVajV
Jacob Plieth
23 Oct 14 03:28:55
Bernstein on $GSK's respiratory biz. $THRX http://t.co/VF9jPsPPAK
Expert Opinion
23 Oct 14 03:16:10
RT @BioStocks: Drugmakers may need indemnity for fast-tracked #Ebola vaccines $JNJ $NLNK $GSK http://t.co/sAe9MjFnqA
MarketCurrents
23 Oct 14 03:09:44
Drugmakers seek indemnity for new Ebola vaccines http://t.co/6MeaJFaxjS $GSK
WKRB News
23 Oct 14 03:07:19
GlaxoSmithKline plc Upgraded at Barclays $GSK http://t.co/6Davo8jYi6
Bio Stocks™
23 Oct 14 03:05:56
Drugmakers may need indemnity for fast-tracked #Ebola vaccines $JNJ $NLNK $GSK http://t.co/sAe9MjFnqA
Joseph Hopkins
23 Oct 14 03:01:22
These rating agencies simply will not allow $GSK to gain any appreciation. JPM is the first of many that just issued negative "reiteration".
Gert Schneider
23 Oct 14 02:55:39
RT @halifaxbroker: Yesterday's top traded #stocks - Tesco $TSCO, Lloyds $LLOY, Quindell $QPP, Rolls-Royce $RR. and GlaxoSmithKline $GSK
Liz Shanahan
23 Oct 14 02:44:15
RT @FiercePharma: $GSK sets $1.6B in new cost cuts, thanks in part to Advair's U.S. formulary discounts http://t.co/LjTkKpcz0A #pharma #mar…
InterCooler
23 Oct 14 02:20:18
GlaxoSmithKline plc’s “Neutral” Rating Reiterated at JPMorgan Chase & Co. $GSK http://t.co/UL9i1TWL4m
WKRB News
23 Oct 14 02:19:57
GlaxoSmithKline plc Short Interest Down 42.0% in September $GSK http://t.co/bTTEu99DgO
Halifax ShareDealing
23 Oct 14 02:18:46
Yesterday's top #FTSE100 risers - Admiral $ADM, Direct Line $DLG, GlaxoSmithKline $GSK, ARM Holdings $ARM and Whitbread $WTB
Halifax ShareDealing
23 Oct 14 02:18:40
Yesterday's top traded #stocks - Tesco $TSCO, Lloyds $LLOY, Quindell $QPP, Rolls-Royce $RR. and GlaxoSmithKline $GSK
Jacob Plieth
23 Oct 14 01:32:24
$GSK's PR strategy working out brilliantly. All the radio chat this morning is about Ebola, ViiV etc. Nothing about respiratory meltdown etc
janet gale
23 Oct 14 00:56:35
$GSK - LONDON MARKETS: Tesco Slumps, Sends FTSE Lower For First Time In Three Days http://t.co/0qleSyhB5r
NASDAQ
23 Oct 14 00:56:31
$GSK - LONDON MARKETS: Tesco Slumps, Sends FTSE Lower For First Time In Three Days http://t.co/C206oqb33v
StockNews
23 Oct 14 00:56:30
$GSK - LONDON MARKETS: Tesco Slumps, Sends FTSE Lower For First Time In Three Days http://t.co/QyETiyx23G
Ken Odeluga
23 Oct 14 00:19:39
Only 3 in the black: $GSK, ICAG,L and RMG.L. 97 in the red -- #FTSE100 right now
US Consumer News
22 Oct 14 23:59:31
GlaxoSmithKline plc's neutral rating reiterated at JPMorgan Chase & Co.. http://t.co/F7BViZDBcL $GSK #GSK
US Consumer News
22 Oct 14 23:59:24
GlaxoSmithKline plc upgraded by Barclays to overweight. GBX 1,600 PT. http://t.co/hQn4UJ8V7A $GSK #GSK
Media Sentiment
22 Oct 14 23:54:55
$GSK received a new alert. Find out why at http://t.co/5udYd0Ofs6 #stocks #daytrading #trading #mkt #NYSE #NASDAQ #markets 752
Analyst Ratings
22 Oct 14 23:53:20
GlaxoSmithKline plc's neutral rating reiterated at JPMorgan Chase & Co.. http://t.co/SJ5cB9hkh5 $GSK #GSK
Analyst Ratings
22 Oct 14 23:53:13
GlaxoSmithKline plc upgraded by Barclays to overweight. GBX 1,600 PT. http://t.co/8OLyDUU834 $GSK #GSK
Sentifi UK_Market
22 Oct 14 23:44:59
$GSK eyes prime FTSE 100 slot for standalone HIV drugs business http://t.co/V8uwFSPPNd More http://t.co/Bne7h8gewg
Sentifi UK_Market
22 Oct 14 23:33:19
TOP 10 Most Discussed $FTSE 100 Companies Today at http://t.co/XZQNh0x0r6 $BATS $LLOY $GSK $ARM $RB $RDSA $WTB $HSBA http://t.co/Y5RdnjVO9K
SharePickers
22 Oct 14 23:32:25
Companies mentioned in the podcast incl: GlaxoSmithKline $GSK. To listen click here> http://t.co/7xU2w9H0BD
RNA_Biotech
22 Oct 14 22:57:47
RT @alexlash: Also just posted this roundup of Ebola pharma news from $JNJ, $TKMR, $GSK and relative newcomer Profectus: http://t.co/eUHi0I…
herbea dro
22 Oct 14 21:48:58
RT @fwpharma: "2014 has been a difficult year, a challenging year," says @GSK CEO Witty http://t.co/wtVghhx0go $GSK #pharma
Stocks Underground
22 Oct 14 21:41:53
$JNJ will have 250,000 #Ebola vaccine doses ready by May 2015. $GSK expects it's own Ebola vaccine doses ready by year end 2014.
Alula H
22 Oct 14 20:45:48
RT @fwpharma: Johnson & Johnson open to combining #Ebola vaccine with GlaxoSmithKline's http://t.co/nT0iDOrgTR $JNJ $GSK #pharma
jjz
22 Oct 14 18:45:56
RT @alexlash: Also just posted this roundup of Ebola pharma news from $JNJ, $TKMR, $GSK and relative newcomer Profectus: http://t.co/eUHi0I…
Nine Stocks
22 Oct 14 18:40:53
MACD(12,26,9) Bull Crossover Stocks (Oct. 22): $AES, $BRCM, $GM, $GSK, $MAS, $SIX http://t.co/8MeMkg6BQh
US Banking News
22 Oct 14 18:38:27
GlaxoSmithKline plc Given New GBX 1,425 Price Target at Panmure Gordon $GSK http://t.co/HIerU4EuTO
INVEX Banco
22 Oct 14 18:30:11
También, $GSK dijo que trabajará junto con otros participantes de la industria para aumentar la escala de la producción
Ryan Baxter
22 Oct 14 18:28:08
RT @chasingthealpha: $RGLS held onto the $GSK termination news for 5 days, then slips it in an 8-K while PRing HCV nonsense. Shady actions
Biotech Beat
22 Oct 14 18:25:41
RT @alexlash: Also just posted this roundup of Ebola pharma news from $JNJ, $TKMR, $GSK and relative newcomer Profectus: http://t.co/eUHi0I…
INVEX Banco
22 Oct 14 18:15:07
$GSK anunció que espera tener la primera dosis de su vacuna contra el #ébola durante este año
Patrick Sikorski
22 Oct 14 18:12:03
RT @chasingthealpha: $RGLS held onto the $GSK termination news for 5 days, then slips it in an 8-K while PRing HCV nonsense. Shady actions
Colin Macleod
22 Oct 14 18:04:50
Nightly Business Report — October 22, 2014 http://t.co/bqEhZPfQsN $JNJ $GSK $BIIB $DOW $SWK $DDD $NSC $CAT $V & More
Fabrice Bosom
22 Oct 14 17:58:26
RT @chasingthealpha: $RGLS held onto the $GSK termination news for 5 days, then slips it in an 8-K while PRing HCV nonsense. Shady actions
On Time Picks
22 Oct 14 17:57:09
DewDiligence: $GSK’s 3Q14 sales of Breo and Anoro were: DewDiligence http://t.co/YZYB54B8Dg
Stock Moo
22 Oct 14 17:54:45
$gsk: [$$] GlaxoSmithKline Unveils Cost-Saving Plan, Considers IPO of HIV Business http://t.co/2D3TDHwoJX
				
				
  +Follow August 16, 2013 9:54AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.